Trial Profile
A randomized double-blind active- and placebo-controlled parallel group safety study assessing simulated driving performance in XP13512 [gabapentin enacarbil] treated patients with restless legs syndrome
Status:
Not stated
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 02 Feb 2007
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions
- 02 Feb 2007 New trial record.